UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Impact of withdrawal of antiepileptic medication on the duration of focal onset seizures

Seizure (London, England), 2019-04, Vol.67, p.40-44

2019

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

Leukemia, 2013-05, Vol.27 (5), p.1072-1079

2013

Link zum Volltext

Verfügbarkeit prüfen

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia

Leukemia, 2011-09, Vol.25 (9), p.1433-1438

2011

Link zum Volltext

Verfügbarkeit prüfen

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

Leukemia, 2012-06, Vol.26 (6), p.1286-1292

2012

Link zum Volltext

Verfügbarkeit prüfen

Targeted antibiotic treatment of lame sheep with footrot using either oxytetracycline or gamithromycin

Veterinary record, 2014-01, Vol.174 (2), p.46-46

2014

Link zum Volltext

Verfügbarkeit prüfen

Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study

Journal of neurology, 2013-08, Vol.260 (8), p.2046-2051

2013

Link zum Volltext

Verfügbarkeit prüfen

The IPSS-R has prognostic impact in untreated patients with MDS del(5q)

Leukemia research, 2018-09, Vol.72, p.27-33

2018

Link zum Volltext

Verfügbarkeit prüfen

Use of impregnated catheters to decrease colonization rates in neonates - A randomized controlled pilot trial

Journal of neonatal-perinatal medicine, 2020, Vol.13 (2), p.231

2020

Link zum Volltext

Verfügbarkeit prüfen

318 THE IPSS-R HAS PROGNOSTIC IMPACT IN UNTREATED PATIENTS WITH MDS DEL(5Q)

Leukemia research, 2015-04, Vol.39, p.S157-S157

2015

Link zum Volltext

Verfügbarkeit prüfen

160 ANALYSIS OF POSSIBLE BIOMARKERS TO PREDICT RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE

Leukemia research, 2015-04, Vol.39, p.S82-S82

2015

Link zum Volltext

Verfügbarkeit prüfen

P-101 Influence of WHO categories and gender on the prognosis of MDS del(5q) patients

Leukemia research, 2013-05, Vol.37, p.S68-S68

2013

Link zum Volltext

Verfügbarkeit prüfen

P14.02 Influence of individual CpG methylation status on outcome in adult patients with glioblastoma multiforme receiving alkylating agent treatment

Neuro-oncology (Charlottesville, Va.), 2019-09, Vol.21 (Supplement_3), p.iii66-iii66

2019

Link zum Volltext

Verfügbarkeit prüfen

Remission status should not be treated as a base-line covariate--reply to Etienne et al

Haematologica (Roma), 2014-09, Vol.99 (9), p.e174

2014

Link zum Volltext

Verfügbarkeit prüfen

Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY

Leukemia research, 2023-05, Vol.128, p.107224, Article 107224

2023

Link zum Volltext

Verfügbarkeit prüfen

Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82

Haematologica (Roma), 2012-05, Vol.97 (5), p.e14-e15

2012

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del

Leukemia, 2013-05, Vol.27 (5), p.1072

2013

Link zum Volltext

Verfügbarkeit prüfen

Effect of cytogenetics at diagnosis on outcome of CML: Results from the randomized German CML Study IV

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6553-6553

2011

Link zum Volltext

Verfügbarkeit prüfen

Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg ± IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.6517-6517

2010

Link zum Volltext

Verfügbarkeit prüfen

Side-effects and complications of foam sclerotherapy of the great and small saphenous veins: a controlled multicentre prospective study including 1,025 patients

Phlebology, 2009-06, Vol.24 (3), p.131

2009

Link zum Volltext

Verfügbarkeit prüfen

CCL1 is a major regulatory T cell attracting factor in human breast cancer

BMC cancer, 2018-12, Vol.18 (1), p.1278-1278, Article 1278

2018

Link zum Volltext

Verfügbarkeit prüfen

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

Journal of clinical oncology, 2014-02, Vol.32 (5), p.415-423

2014

Link zum Volltext

Verfügbarkeit prüfen

SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment

Leukemia & lymphoma, 2022-03, Vol.63 (4), p.955-962

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.33-33

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 56

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(56)

Sprache

Englisch
(54)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(18)
Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Female
(14)
Male
(14)
Aged
(11)
Hematology
(11)
Middle Aged
(11)
Adult
(9)
Aged, 80 And Over
(9)
Oncology
(9)
Treatment Outcome
(9)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(8)
Risk Factors
(7)
Adolescent
(6)
Antineoplastic Agents - Therapeutic Use
(5)
Imatinib Mesylate
(5)
Patients
(5)
Benzamides - Therapeutic Use
(4)
Chronic Myeloid Leukemia
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(24)
Journal Of Clinical Oncology
(7)
Leukemia
(5)
Leukemia Research
(5)
Haematologica
(4)
Annals Of Hematology
(1)
Archives Françaises De Pediatrie
(1)
Bmc Cancer
(1)
Journal Of Neonatal-Perinatal Medicine
(1)
Journal Of Neurology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

Impact of withdrawal of antiepileptic medication on the duration of focal onset seizures

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

Targeted antibiotic treatment of lame sheep with footrot using either oxytetracycline or gamithromycin

Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study

The IPSS-R has prognostic impact in untreated patients with MDS del(5q)

Use of impregnated catheters to decrease colonization rates in neonates - A randomized controlled pilot trial

318 THE IPSS-R HAS PROGNOSTIC IMPACT IN UNTREATED PATIENTS WITH MDS DEL(5Q)

160 ANALYSIS OF POSSIBLE BIOMARKERS TO PREDICT RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE

P-101 Influence of WHO categories and gender on the prognosis of MDS del(5q) patients

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

P14.02 Influence of individual CpG methylation status on outcome in adult patients with glioblastoma multiforme receiving alkylating agent treatment

Remission status should not be treated as a base-line covariate--reply to Etienne et al

Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY

Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del

Effect of cytogenetics at diagnosis on outcome of CML: Results from the randomized German CML Study IV

Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg ± IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV

Side-effects and complications of foam sclerotherapy of the great and small saphenous veins: a controlled multicentre prospective study including 1,025 patients

CCL1 is a major regulatory T cell attracting factor in human breast cancer

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Aktive Filter

Suchergebnisse filtern